Radiopharmaceutical Therapy: Program Justification, Start-up and AU Pathways

This educational activity is comprised of two sessions:

Radiopharmaceutical Program Justification and Initial Start-Up
This session addresses the initial steps required for building a radiopharmaceutical program. Crucial to starting a program is understanding the business case, which includes understanding the potential referral stream, reimbursement, personnel, space, and equipment costs to start a program. Speakers discuss space, radioactive materials license, protocol requirements for starting a program, and clinic and staffing needs. 

Authorized User Pathways and Physicist Training in Radiopharmaceutical Therapy
This session explores two essential components of a successful RPT program: authorized user credentialing process and structured training for medical physicists. It includes a step-by-step overview of the regulatory pathway for obtaining AU status, including required training and documentation. In addition, clinical training experiences for medical physicist to support RPT is shared.   

This activity is available from December 1, 2026, through 11:59 p.m. Eastern time on November 30, 2028.

The content was originally presented and recorded at the 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium.

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, and radiation physicists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Identify the “why” of their radiopharmaceutical therapy (RPT) program.
  2. Discuss the basic practice economics for RPTs in the freestanding and hospital setting.
  3. Outline space requirements for RPT administration.
  4. Understand the authorized user pathway.
  5. Outline strategies for optimizing their RPT service line.
  6. Recognize resources needed for a functioning RPT clinic.
  7. Identify some of the regulatory underpinnings of these resource requirements.
  8. Outline physicist training resources and needs.
  9. Identify the training and experience needed to satisfy the NRC requirements for authorized user for unsealed byproduct material requiring a written directive.
  10. Identify radionuclide calibrator, SPECT/CT, and PET/CT QA/QC roles and needs.

Course summary

Available credit: 
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
12/01/2026
Course expires: 
11/30/2028
Cost:
$229.00
Rating: 
0

Radiopharmaceutical Program Justification and Initial Start-up

Moderator: Ramji R. Rajendran, MD, PhD, Radiation Oncology Consultants Ltd.

  • Practice Economics for Radiopharmaceutical Therapy: From Mission to Margin
    Dustin L. Boothe, MD, Intermountain Health, Utah Cancer Specialists
  • Space Requirements for RPT Administration
    J. Travis Mendel, MD, Rio Grande Cancer Specialists
  • The RAM License and SOP Development
    Ashley Cockerham, MSJ, Mercurie Consulting, LLC
  • Clinic and Staffing Needs for RPT Delivery
    Brett E. Lewis, MD, PhD, Hackensack University Medical Center

Authorized User Pathways and Physicist Training in Radiopharmaceutical Therapy

Moderator: Xinxin Zhang, PhD, Rutgers Cancer Institute of New Jersey/Robert Wood Johnson University Hospital

  • The Path to Authorized User for Unsealed Byproduct Material
    Robert J. Tokarz, MS, DABR, RJ Tokarz Medical Imaging Radiation Safety Corp
  • Physicist Training in RPT: The Beginnings of Structured Programs
    Robert Hobbs, PhD, DABR, Johns Hopkins University
  • QA and QC for Dose Calibrators, SPECT/CT and PET/CT Systems for Radiopharmaceutical Therapy
    John J. Sunderland, PhD, MBA, The University of Iowa

Moderators:

  • Xinxin Zhang, PhD is employed by Robert Wood Johnson University Hospital/Rutgers Cancer Institution and has no relevant financial relationships to disclose.
  • Ramji R. Rajendran, MD, PhD is employed by Radiation Oncology Consultants. Dr. Rajendran is an Advisory Board and Speakers Bureau member for Novocure and AstraZeneca; Consultant for Bekton Dickinson; Consultant and Speakers Bureau member for Telix Pharmaceuticals; Advisory Board member for Novartis and ArteraAI; and has grant/research funding [institution] from Novartis and Radiopharm Theranostics.

Speakers:

  • Dustin L. Boothe, MD is employed by Intermountain Health. Dr. Boothe is an Advisory Board member and Consultant for Cellectar Biosciences [ended 12/31/2024]; Advisory Board member for GE Healthcare [ended 7/1/2025] and Bayer [ended 10/1/2025]; Speaker Bureau member for Varian [ended 12/8/2025]; and received compensation from Novartis [ended 2/15/2025].
  • J. Travis Mendel, MD is employed by Rio Grande Urology. Dr. Mendel is a Consultant for BioProtect, GE, Novartis, and Bayer [ended 12/18/2024]; education/meeting faculty for LUGA; and receives grant/research funding [institution] from Novartis.
  • Ashley Cockerham, MSJ is employed by Mercurie Consulting, LLC and is a Consultant for Bayer Pharmaceuticals, Boston Scientific, GT Medical Technologies, Helion, NorthStar Medical Radioisotopes, OncoBeta, Serva Energy, Terumo Medical, and Z-Alpha Therapeutics​.
  • Brett E. Lewis, MD, PhD is employed by UPMC Williamsport and Mountainside Medical center of Ardent Health. Dr. Lewis was an Advisory Board member for Novartis [ended 7/8/2025].
  • Robert J. Tokarz, MS, DABR owns RJ Tokarz Medical Imaging Radiation Safety Corp. and has no relevant financial relationships to disclose
  • Robert Hobbs, PhD, DABR, Johns Hopkins University is employed by Johns Hopkins Medical Institute. Dr. Hobbs is a consultant for Boston Scientific, Mirion, AstraZeneca, and Vios [ended 1/31/25]; and has a copyright licensed to RAPID Dosimetry.
  • John J. Sunderland, PhD, MBA is employed by the University of Iowa and has no relevant financial relationships to disclose.

Planner:

  • Malcolm Mattes, MD, is employed by Rutgers Cancer Institute. Dr. Mattes has research funding from Gilead Sciences [ended 8/30/2025].

Reviewer:

  • Michael Haddock, MD is employed by Mayo Clinic and has no relevant financial relationships to disclose.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$229.00
Please login or register to take this course.

Activity Fees

This activity is included in the ASTRO Academy Subscription. To purchase the subscription beginning December 1, 2026, please go to the ASTRO Product Catalog.

ASTRO members and Academy subscribers must log in to the ASTRO Academy to view and receive the corresponding rate:

  • Academy Subscriber: $0
  • Member: $99
  • Member-in-Training / Student Member / Postdoctoral Fellow Member: $49
  • Nonmember: $149

Discounts
Please email ASTRO eLearning to inquire about the discounts below.

  • If you are an ASTRO member residing in a low- or lower-middle-income economy country, as identified by the World Bank, you can receive a 50% discount off the activity fee.
  • If you are an ASTRO member residing in an upper-middle-income economy country, as identified by the World Bank, you can receive a 25% discount off the activity fee.

Policies

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until the Activity expiration date, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Copyright of all aspects of ASTRO Academy Content, including recordings and/or reproductions of sessions, programs, presentations, discussions and other scheduled events (“ASTRO Academy Content”) is owned by ASTRO. Only ASTRO reserves the rights to all ASTRO Academy Content, including to digitize, modify, alter, edit, adapt, create derivative works, display, publicly perform, exhibit, transmit, broadcast, reproduce, exploit, sell, rent license, otherwise use, and permit others to use, such ASTRO Academy Content. Photographing, filming, taping, recording or any form of capture or reproduction in any medium of any aspect of ASTRO Academy Content, including, but not limited to the programs, presentations, material, sessions, and discussions, or on the Academy platform are strictly forbidden without written authorization from ASTRO.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.